CEL-SCI Corporation announced that it intends to offer to sell shares of its common stock in an underwritten public offering. The company intends to use the net proceeds from this offering to fund the continued development of Multikine and for general corporate purposes. ThinkEquity is acting as sole book-running manager for the offering.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CVM:
- Cel-Sci (NYSE:CVM) Plummets on $5M Stock Offering
- CEL-SCI concludes provides update on Multikine immunotherapy path to market
- CEL-SCI: Multikine can be effective in extending life for head & neck cancer
- CEL-SCI to present data from Phase 3 study in SCCHN at AHNS Conference
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue